

**Medicaid Preferred Drug List (PDL) Program:  
Quarterly Meeting  
Pharmacy and Therapeutics Committee  
Wednesday, August 31, 2005  
9:00 a.m., DMAS Board Room  
REVISED AGENDA: No Quorum\***

- **Welcome and Introductions** **Patrick W. Finnerty, Director**
  
  - **Comments from the Secretary of Health and Human Resources** **The Honorable Jane H. Woods,  
Secretary of Health and Human  
Resources**
  
  - **Comments from the Chairperson** **Randy Axelrod, M.D., Chairman**
  
  - **Management of Specialty Drug Classes** **Randy Axelrod, M.D., Chairman**
  
  - **Evaluation of PDL Program** **Wayne Turnage, DMAS Policy &  
Research**
  
  - **Impact of Medicare Part D Implementation** **Jack Quigley, DMAS Policy**  
  
**Justin Lester, First Health Services  
Corporation, Rebate Contracting**
  
  - **New Drug Class Discussions** **P&T Committee Members**
- Review of New Drug Classes for PDL Eligibility**
- Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
  - Phosphodiesterase 5 Inhibitor for Pulmonary Arterial Hypertension
- 
- **Next Meeting – October 19, 2005, 9 a.m.** **Randy Axelrod, M.D., Chairman**

*\* Because there is no quorum, the Committee will not be able to vote on new drugs or drug classes at this meeting. Any information presented, will be provided to the absent members and addressed at the October 19<sup>th</sup> meeting.*